skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Greetings, Peter, Ryan and Co.
I am trying to evaluate the upside potential of ImmunoPrecise Antibodies (IPA.V), a microcap in the very dangerous junior biotech sector. I would appreciate any insights/opinion that you might have, if any, and any sources you would recommend I use to do some more due diligence. My usual sources are of little value.
With appreciation.
Ed
Read Answer Asked by Ed on April 17, 2017
Q: Hi Peter,

I have had ESP for 2-3 years and I have seen it as high as $4 when a potential deal with Rogers was in the works. It is currently my largest holding. ESP's last quarter was very positive and gave the price a good bump which has since dwindled. With approximatley $1.15 per share in cash, can we assume 1.5 X cash = $1.72 as a minimum value for this company? This has been the valuation I am basing my decisions on. With the current price approaching $2 a share (my average), I see good potential with manageable risk.

I look forward to your opinion on this one.

Cheers,
Read Answer Asked by Ryan on April 13, 2017
Q: How do you interpret this news about SNA? ... (April 5) .. "delisted from the TSX Venture Exchange ("TSX-V") after the close of trading on Thursday, April 6, 2017 and will be listed on the Canadian Securities Exchange ("CSE")" .. and a little jump in the price today .. what does this move from one exchange to another mean exactly? .. is there anything significant here? thanks
Read Answer Asked by Patrik on April 13, 2017
Q: in which order would you sell the above names? Are there any catalysts that might move the stock price in the next couple of months ?
Read Answer Asked by Shawn on April 12, 2017
Q: RenoWorks (RW-TSXV) develops and distributes digital visualization software for the renovation and new home construction industry - clients can visualize and evaluate various alternatives (e.g. colours, textures, materiels etc.) making it a lot easier to 'close the deal'. They claim that the digital visualization software imaging industry is currently in its infancy with few independent participants who match the breadth of their offerings. Insiders own ~ 50%.

Their year-end (and Q4) report on Friday showed significant progress - Q4 revenue was up 67% yoy with recurring revenue representing 56%. Though still in a net loss situation, they were Adjusted EBITDA positive for Q3 and Q4, as well as for 2016 overall.

Would appreciate your always well-measured take on this microcap.

Thanks
Read Answer Asked by Richard on April 10, 2017
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!